Introduction

49
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and lethal lung disease of from all subjects.
103
Cell Culture
104
Primary HLFs from 8 patients with IPF and 10 controls were cultured from lung explants as 105 described previously and used at passage 5 (10). HLFs were treated for 48 hr with human 106 recombinant FGF9 (20 ng/ml) (R&D Systems, Minneapolis, MI, USA) or FGF18 (20 ng/ml)
107
(Sigma), in the presence of heparin Choay (100 µg/ml) because heparin is essential for FGF 108 signaling (4) (45). In preliminary dose-finding experiments, we determined that a 109 concentration of 20 ng/ml for FGF9 and FGF18 was optimal to induce ERK phosphorylation 110 at 10 min (data not shown). Heparin alone was a control (ctr. 
148
For immunofluorescence, cells were cultured in full growth medium on Permanox Lab-Tek
149
Chamber Slides (Nunc, Thermo Fisher Scientific, Rochester, NY, USA) as described (10).
150
The primary antibody was anti-α-SMA (clone 1A4, Sigma-Aldrich). Actin fibers and nuclei
151
were stained with phalloidin-coupled Alexa568 dye (Invitrogen), then DAPI (Invitrogen).
152
Light microscopy images were acquired with a DM400B light microscope (Leica) equipped 153 with a Leica DFC420 CDD camera. Immunofluorescence images were acquired with an IX70 154 fluorescence microscope (Olympus) equipped with an X-cite Q source and an ORCA-03G
155
CCD camera (Hamamatsu) with Cell-A software (Olympus).
156
Protein Analysis
157
Primary fibroblasts in culture were lyzed on ice in RIPA buffer supplemented with protease 158 inhibitor cocktail as described (10). Primary antibodies were anti-α-SMA (clone 1A4, Sigma- lungs (n=36) ( Figure 1A ). control and IPF fibroblasts ( Figure 3B ), whereas FGF18 inhibited control fibroblast growth 222 but had no effect on IPF fibroblasts ( Figure 3B ). In parallel, lung fibroblasts were stimulated 
FGF9 and FGF18 Modulate Myofibroblast Differentiation in Control and IPF
237
Fibroblasts
238
Differentiation of fibroblasts into myofibroblasts is an important step in pulmonary fibrosis.
239
We assessed the effect of FGF9 and FGF18 on collagen-1 and α-smooth muscle actin (α-240 SMA) expression. In the basal condition, FGF9 downregulated collagen-1 and α-SMA protein 241 expression in both control ( Figure 4A ) and IPF fibroblasts ( Figure 4B ). These results were 242 confirmed at the mRNA level ( Figure 4C, 4D) . Conversely, FGF18 decreased A1COL1 and
243
ACTA2 mRNA expression in control fibroblasts ( Figure 4C ) but had no significant effect on
244
IPF fibroblasts ( Figure 4D ) and did not affect collagen-1 and α-SMA protein expression. As Figure 5C ). These results were confirmed at the 254 mRNA level ( Figure 5D ). Strikingly, the protective effect of FGF9 was limited to control 255 fibroblasts as FGF9 had no effect on IPF fibroblasts ( Figure 5B , 5C, 5E). 
262
Altogether, these data demonstrate that FGF9 partially prevented the myofibroblastic 263 differentiation of control and IPF fibroblasts induced by TGF-β1, but FGF18 had almost no 264 effect. FGF1 was a more potent inhibitor in these culture conditions.
266
FGF9 and FGF18 Enhance Migration of Control and IPF Lung Fibroblasts
267
Migration is an important step in fibrosis that allows fibroblasts or myofibroblasts to 268 accumulate into fibroblast foci and participate in the fibrotic process (15). We tested the effect 
FGF9 and FGF18 Regulate MMP Expression in Control and IPF Lung Fibroblasts
278
To elucidate the mechanism by which FGF9 and FGF18 promote a migratory phenotype, we were clearly more potent on control than IPF fibroblasts.
321
A summary of the differential effect of FGF9, FGF18 and FGF1 is shown in Table 2 . known FGFRs (44). This observation might explain the strong effect of FGF1 we observed.
419
Our data also showed that FGFR3 partial knockdown with siRNA was sufficient to clearly 420 impact FGF9 and FGF18 effects on migration and basal myofibroblastic differentiation. Table 2 ).
428
In conclusion, our results identify FGF9 as a potent anti-apoptotic, anti-differentiation 429 and pro-migratory growth factor in lung fibroblasts and strongly suggest that FGF9 and
430
FGF18 participate in IPF pathophysiology by promoting fibroblast phenotype changes. 
709
For TGF-β1-induced myofibroblastic differentiation, control and IPF fibroblasts were 710 pretreated for 1 hr with FGF9, FGF18 and FGF1 (20 ng/ml), then TGF-β1 (1 ng/ml) for 48 hr. 
